Literature DB >> 7513156

Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1.

D Taskiran1, M Stefanovic-Racic, H Georgescu, C Evans.   

Abstract

Slices of rabbit articular cartilage synthesized large quantities of nitric oxide (NO) following exposure to human recombinant interleukin-1 beta (hrIL-1 beta) or rabbit synovial cytokines (CAF). Each of these stimuli also strongly suppressed the biosynthetic incorporation of 35SO4(2-) into the glycosaminoglycans (GAGs) of cartilage proteoglycans. Treatment of cartilage fragments with L-NG-monomethylarginine (L-NMA), a competitive inhibitor of NO synthase, both inhibited NO synthesis in response to IL-1 and CAF and restored proteoglycan synthesis. D-NMA was inactive in this regard, and L-arginine reversed the effects of L-NMA. S-nitrosylacetylpenicillamine (SNAP), an organic donor of NO, reversibly mimicked the effect of IL-1 and CAF on 35SO4(2-) incorporation. These data suggest that endogenously synthesized NO is the mediator which reduces cartilage proteoglycan synthesis in response to cytokines such as IL-1 and CAF. Antagonists of NO production may promote cartilage matrix synthesis and thus have potential as chondroprotective or chondroreparative agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513156     DOI: 10.1006/bbrc.1994.1426

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  76 in total

1.  Modulation of nitric oxide synthase activity by ibuprofen.

Authors:  J E Menzel; G Kolarz
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

2.  Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra.

Authors:  L A Joosten; M M Helsen; W B van Den Berg
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Selenomethionine inhibits IL-1β inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2) expression in primary human chondrocytes.

Authors:  A W M Cheng; T V Stabler; M Bolognesi; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2010-10-28       Impact factor: 6.576

Review 4.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Outside-in signaling in the chondrocyte. Nitric oxide disrupts fibronectin-induced assembly of a subplasmalemmal actin/rho A/focal adhesion kinase signaling complex.

Authors:  R M Clancy; J Rediske; X Tang; N Nijher; S Frenkel; M Philips; S B Abramson
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

6.  Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints.

Authors:  Kenta Matsuda; Shigeru Nakamura; Takashi Matsushita
Journal:  Rheumatol Int       Date:  2006-01-26       Impact factor: 2.631

7.  Tumor necrosis factor alpha-dependent proinflammatory gene induction is inhibited by cyclic tensile strain in articular chondrocytes in vitro.

Authors:  P Long; R Gassner; S Agarwal
Journal:  Arthritis Rheum       Date:  2001-10

Review 8.  Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes.

Authors:  P J Verschure; C J Van Noorden; J Van Marle; W B Van den Berg
Journal:  Histochem J       Date:  1996-12

Review 9.  Chondropenia: current concept review.

Authors:  A Speziali; M Delcogliano; M Tei; G Placella; M Chillemi; R Tiribuzi; G Cerulli
Journal:  Musculoskelet Surg       Date:  2015-06-13

10.  Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production.

Authors:  Katriina Vuolteenaho; Anna Koskinen; Meiju Kukkonen; Riina Nieminen; Unto Päivärinta; Teemu Moilanen; Eeva Moilanen
Journal:  Mediators Inflamm       Date:  2009-08-13       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.